TIAA CREF Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

TIAA CREF Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.01M	Buy	64,068 +6,423	+11%	+$111K	﹤0.01%	2317
2018 Q4	$1.16M	Sell	57,645 -18,040	-24%	-$397K	﹤0.01%	2228
2018 Q3	$1.88M	Sell	75,685 -35,935	-32%	-$977K	﹤0.01%	2147
2018 Q2	$3.06M	Buy	111,620 +44,385	+66%	+$1.33M	﹤0.01%	1938
2018 Q1	$2.07M	Buy	67,235 +4,372	+7%	+$141K	﹤0.01%	2078
2017 Q4	$2.25M	Buy	62,863 +2,759	+5%	+$79.2K	﹤0.01%	2071
2017 Q3	$1.66M	Buy	60,104 +595	+1%	+$14.4K	﹤0.01%	2265
2017 Q2	$1.57M	Sell	59,509 -15,765	-21%	-$352K	﹤0.01%	2324
2017 Q1	$1.57M	Sell	75,274 -2,413	-3%	-$49.6K	﹤0.01%	2280
2016 Q4	$1.61M	Buy	77,687 +6,534	+9%	+$109K	﹤0.01%	2300
2016 Q3	$1.15K	Buy	71,153 +9,564	+16%	+$139K	﹤0.01%	2471
2016 Q2	$838K	Buy	61,589 +5,874	+11%	+$104K	﹤0.01%	2605
2016 Q1	$973K	Hold	55,715	–	–	﹤0.01%	2484
2015 Q4	$1.9M	Buy	55,715 +3,187	+6%	+$110K	﹤0.01%	2186
2015 Q3	$1.56M	Sell	52,528 -1,155	-2%	-$35.1K	﹤0.01%	2294
2015 Q2	$1.72M	Buy	53,683 +22,050	+70%	+$567K	﹤0.01%	2398
2015 Q1	$656K	Buy	31,633 +2,240	+8%	+$38.7K	﹤0.01%	2833
2014 Q4	$498K	Buy	29,393 +521	+2%	+$9.1K	﹤0.01%	2966
2014 Q3	$558K	Hold	28,872	–	–	﹤0.01%	2929
2014 Q2	$982K	Buy	28,872 +6,794	+31%	+$213K	﹤0.01%	2735
2014 Q1	$695K	Buy	+22,078	New	+$690K	﹤0.01%	2825

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

TIAA CREF Investment Management's RVNC Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Revance Therapeutics, Inc. (RVNC) stake by 11% in Q1 2019, buying an estimated $111K and bringing the position to 64,068 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

TIAA CREF Investment Management first reported a position in RVNC in Q1 2014 and has held it in 21 quarters since. The position peaked at $3.06M in Q2 2018. 112 funds tracked by Wall St. Rank hold RVNC as of Q1 2019.

TIAA CREF Investment Management held 64,068 shares of Revance Therapeutics, Inc. worth $1.01M as of Q1 2019.
TIAA CREF Investment Management bought 6,423 Revance Therapeutics, Inc. shares in Q1 2019, an estimated $111K.
Revance Therapeutics, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2317 holding.
TIAA CREF Investment Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and has held it in 21 quarters since.
TIAA CREF Investment Management's Revance Therapeutics, Inc. position peaked at $3.06M in Q2 2018.
112 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.